LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Garrido, Pilar; Paz‐Ares, Luis; Majem, Margarita; Morán, Teresa; Trigo, José; Bosch-Barrera, Joaquim; García‐Campelo, Rosario; Gonzalez-Larriba, J. L.; Sánchez-Torres, J.M.; Isla, Dolores; Viñolas, Núria; Camps, Carlos; Insa, Amelia; Juan, Óscar; Massutí, Bartomeu; Paredes, Alfredo; Artal, A.; López‐Brea, Marta; Palacios, José; Felip, Enriqueta

doi:10.1002/cam4.4135

Cited by 12 publications

(11 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mutant allele dynamics of T790M and the major activating mutations were expected to be identical. The dynamics of ctDNA, especially the disappearance of mutant alleles after the introduction of osimertinib, have been reported to predict long-term efficacy 35 – 37 . Consistent with this result, in the present study, we observed a trend toward a longer response to osimertinib in patients showing early disappearance of T790M and major activating mutation alleles; however, the difference was not significant.…”

Section: Discussionmentioning

confidence: 99%

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC

Kunimasa

Nishino

Sato

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received osimertinib; the samples were collected after second-line treatment, before osimertinib treatment, one week and one month after osimertinib treatment, and at the time of resistance formation. We examinedthe correlation with osimertinib efficacy. From January to December 2018, 34 patients with EGFR-mutated NSCLC harboring EGFR T790M mutations were enrolled, and a total of 132 peripheral blood samples were collected. The fragment sizes of EGFR-mutated ctDNAs were significantly shorter than that of their corresponding normal fragments. Osimertinib treatment of patients with shorter EGFR-mutated ctDNA fragments resulted in shorter progression-free survival (PFS). The disappearance time of EGFR-mutated fragment fractions and clonal evolution patterns (new driver mutation group, additional mutation group vs. attenuation group) were each associated with the PFS achieved with osimertinib treatment; however,multivariate analysis revealed that only shorter EGFR-mutated ctDNA fragments were associated with the PFS resulting from osimertinib treatment. EGFR-mutated ctDNA fragment size, time of disappearance of these fragments, and clonal evolution pattern were related to the effects of osimertinib. In particular, short EGFR-mutated ctDNA fragmentation may be closely related to osimertinib efficacy prediction.

show abstract

Section: Discussionmentioning

confidence: 99%

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC

Kunimasa

Nishino

Sato

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…LungBEAM, a prospective study across 19 Spanish hospitals, collected serial blood specimens at baseline from 110 treatment-naïve patients with advanced EGFR -mutant NSCLC and monthly for EGFR T790M emergence while on first-line EGFR TKI therapy until radiographic progression [ 90 ]. Progression was observed in 68 of the 110 patients (61.8%) who completed the study.…”

Section: Treatment Response Monitoringmentioning

confidence: 99%

“…Progression was observed in 68 of the 110 patients (61.8%) who completed the study. Twenty-six patients (23.6%) showed the presence of an EGFR T790M mutation in plasma, with detection at a median of 76 days prior to radiographic progression [ 90 ].…”

Section: Treatment Response Monitoringmentioning

confidence: 99%

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer

Shields

Chen

Dutcher

et al. 2022

IJMS

View full text Add to dashboard Cite

Advancements in the clinical practice of non-small cell lung cancer (NSCLC) are shifting treatment paradigms towards increasingly personalized approaches. Liquid biopsies using various circulating analytes provide minimally invasive methods of sampling the molecular content within tumor cells. Plasma-derived circulating tumor DNA (ctDNA), the tumor-derived component of cell-free DNA (cfDNA), is the most extensively studied analyte and has a growing list of applications in the clinical management of NSCLC. As an alternative to tumor genotyping, the assessment of oncogenic driver alterations by ctDNA has become an accepted companion diagnostic via both single-gene polymerase chain reactions (PCR) and next-generation sequencing (NGS) for advanced NSCLC. ctDNA technologies have also shown the ability to detect the emerging mechanisms of acquired resistance that evolve after targeted therapy. Furthermore, the detection of minimal residual disease (MRD) by ctDNA for patients with NSCLC after curative-intent treatment may serve as a prognostic and potentially predictive biomarker for recurrence and response to therapy, respectively. Finally, ctDNA analysis via mutational, methylation, and/or fragmentation multi-omic profiling offers the potential for improving early lung cancer detection. In this review, we discuss the role of ctDNA in each of these capacities, namely, for molecular profiling, treatment response monitoring, MRD detection, and early cancer detection of NSCLC.

show abstract

“…The DNA can then be released from the beads and analyzed with flow cytometry or optical scanning instruments to locate mutation ( 16 , 17 ). A recent LungBEAM study demonstrated the great potential of BEAMing in optimizing treatment in patients with advanced NSCLC ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer

Fang

Yu²,

Jiang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA) has contributed immensely to the management of hematologic malignancy and is now considered a valuable detection tool for solid tumors. ctDNA can reflect the real-time tumor burden and be utilized for analyzing specific cancer mutations via liquid biopsy which is a non-invasive procedure that can be used with a relatively high frequency. Thus, many clinicians use ctDNA to assess minimal residual disease (MRD) and it serves as a prognostic and predictive biomarker for cancer therapy, especially for non-small cell lung cancer (NSCLC). Advanced methods have been developed to detect ctDNA, and recent clinical trials have shown the rationality and feasibility of ctDNA for identifying mutations and guiding treatments in NSCLC. Here, we have reviewed recently developed ctDNA detection methods and the importance of sequence analyses of ctDNA in NSCLC.

show abstract

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 12 publications

References 44 publications

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer

Contact Info

Product

Resources

About